BETHESDA, Md., Oct. 2 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) announced today that Anthony P. Deasey, 58, has been appointed as the Company's Senior Vice President of Finance and Chief Financial Officer, and has been elected to the Board of Directors.
Prior to joining NWBT, from November 2000 to September 2007 Mr. Deasey served as Executive Vice President, Chief Financial and Chief Operating Officer of Celsion Corporation, a biotechnology company headquartered in Columbia, Maryland. At Celsion, Mr. Deasey played a key role in transitioning Celsion from a medical device to an oncology drug development company, and acquired substantial experience with oncology regulatory and market factors. In addition to Celsion, Mr. Deasey previously served as Chief Financial Officer of two public companies with domestic and international operations and a diverse range of products with up to $800 million in revenues.
"We are very pleased to announce the appointment of Tony as our Chief Financial Officer," said Alton Boynton, PhD, President and Chief Executive Officer of Northwest Biotherapeutics. "As we are in the process of establishing international operations and accelerating our pivotal studies in the United States, Tony's extensive financial, operational and management experience, and his familiarity with the oncology sector, will be a valuable addition to our team."
ABOUT NORTHWEST BIOTHERAPEUTICS, INC.
Northwest Biotherapeutics, Inc. is a US-based biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, and on a cost-effective basis.
The Company has two lead product candidates:
1. DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of
Glioblastoma multiforme; and
2. DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment
|SOURCE Northwest Biotherapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved